These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 19267726)

  • 1. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
    Marcu LG
    Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for use of amifostine in cervical cancer.
    Small W
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
    Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
    Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
    Wadler S; Goldberg G; Fields A; Anderson P; Beitler JJ; Sood B; Haynes H; Runowicz C
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):64-8. PubMed ID: 8783670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
    Bernier J; Cooper JS; Pajak TF; van Glabbeke M; Bourhis J; Forastiere A; Ozsahin EM; Jacobs JR; Jassem J; Ang KK; Lefèbvre JL
    Head Neck; 2005 Oct; 27(10):843-50. PubMed ID: 16161069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine and curative intent chemoradiation for compromised cancer patients.
    Nguyen NP; Levinson B; Dutta S; Karlsson U; Kelly KC; Dowell J; Ludin A; Sallah S
    Anticancer Res; 2003; 23(2C):1649-56. PubMed ID: 12820436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stochastic modelling of the role of cisplatin in altered fractionation schedules for head and neck cancer.
    Marcu L; Bezak E
    Phys Med; 2010 Oct; 26(4):177-83. PubMed ID: 20034829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head and neck squamous cell carcinoma: optimizing the therapeutic index.
    Rosenthal DI; Blanco AI
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):501-14. PubMed ID: 16001957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
    Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
    J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
    Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
    [No Abstract]   [Full Text] [Related]  

  • 15. A new administration schedule for amifostine as a radioprotector in cancer therapy.
    Wagner W; Radmard A; Schönekaes KG
    Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approach.
    Marcu L; Bezak E; Olver I
    Phys Med Biol; 2006 Aug; 51(15):3625-37. PubMed ID: 16861770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.
    Büntzel J; Glatzel M; Mücke R; Micke O; Bruns F
    Anticancer Res; 2007; 27(4A):1953-6. PubMed ID: 17649803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II trial of amifostine for head and neck irradiation in lymphoma.
    Ng AK; Hickey G; Li S; Neuberg D; Mauch PM
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):20-4. PubMed ID: 15726518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoradiotherapy for head and neck cancer: 'local' side effects are actually systemic.
    J Support Oncol; 2006 Feb; 4(2):88. PubMed ID: 16499131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.